Model organisms: Animal models of sepsis: Setting the stage

Nature Reviews Drug Discovery

Volumn 4, Issue 10, 2005, Pages 854-865

  Buras, Jon A ^a   Holzmann, Bernhard ^b   Sitkovsky, Michail ^c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c NORTHEASTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ADENOSINE A2 RECEPTOR; AFELIMOMAB; ANTIINFLAMMATORY AGENT; APOPTOSIS INDUCING FACTOR; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; CYTOKINE; DROTRECOGIN; HIGH MOBILITY GROUP B1 PROTEIN; HIGH MOBILITY GROUP PROTEIN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

CARDIOVASCULAR SYSTEM; CLINICAL STUDY; CLINICAL TRIAL; DISEASE MODEL; DISEASE SIMULATION; DRUG TARGETING; ENDOCRINE SYSTEM; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; INFECTION; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPSIS; ANIMAL; COMPARATIVE STUDY; ENTEROPATHY; METHODOLOGY; PATHOPHYSIOLOGY;

ANIMALS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HUMANS; INTESTINAL DISEASES; SEPSIS;

EID: 27644577000     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd1854     Document Type: Review

References (107)

1. Angus, D.C. et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29, 1303-1310 (2001).
2. Panacek, E. A. et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab′)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit. Care Med. 32, 2173-2182 (2004).
3. Natanson, C., Hoffman, W. D., Suffredini, A. F., Eichacker, P. Q. & Danner, R. L. Selected treatment strategies for septic shock based on proposed mechanisms of pathogenesis. Ann. Intern. Med. 120, 771-783 (1994).
4. Riedemann, N. C., Guo, R. F. & Ward, P. A. The enigma of sepsis. J. Clin. Invest. 112, 460-467 (2003).
5. Marshall, J. C. Such stuff as dreams are made on: Mediator directed therapy in sepsis. Nature Rev. Drug Discov. 2, 391-405 (2003).
6. Zeni, F., Freeman, B. & Natanson, C. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit. Care Med. 25, 1095-1100 (1997).
7. Sitkovsky, M. V. & al., e. Physiological control of immune response and inflammatory tissue damage by hypoxia inducible factors and adenosine A2A receptors. Annu. Rev. Immunol 22, 2101-2126 (2004).
8. Freeman, B. D. et al. Role of CuZn superoxide dismutase in regulating lymphocyte apoptosis during sepsis. Crit. Care Med. 28, 1701-1708 (2000).
9. Yang, H. et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc. Natl Acad. Sci. USA 101, 296-301 (2004).
10. Ward, P. A. The dark side of C5a in sepsis. Nature Rev. Immunol. 4, 133-142 (2004).
11. Akira, S. & Hemmi, H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol. Lett. 85, 85-95 (2003).
12. Beutler, B. Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430, 257-263 (2004).
13. Bone, R. C. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit. Care Med. 24, 1125-1128 (1996).
14. Ulloa, F. & Tracey, K. J. The 'cytokine profile': A code for sepsis. Trends Mol. Med. 11, 56-63 (2005).
15. Bone, R. C. et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/ Society of Critical Care Medicine. Chest 101, 1644-1655 (1992).
16. Levy, M. M. et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit. Care Med. 31, 1250-1256 (2003).
17. Opal, S. M. The uncertain value of the definition for SIRS. Systemic inflammatory response syndrome. Chest 113, 1442-1443 (1998).
18. Cohen, J. et al. New strategies for clinical trials in patients with sepsis and septic shock. Crit. Care Med. 29, 880-886 (2001).
19. Bernard, G. R. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699-709 (2001).
20. Wichterman, K. A., Bane, A. E. & Chaudry, I. H. Sepsis and septic shock-a review of laboratory models and a proposal. J. Surg. Res. 29, 189-201 (1980).
21. Fink, M. P. & Heard, S. O. Laboratory models of sepsis and septic shock. J. Surg. Res. 49, 186-196 (1990).
22. Deitch, E. A. Animal models of sepsis and shock: A review and lessons learned. Shock 9, 1-11 (1998).
23. Esmon, C. T. Why do animal models (sometimes) fail to mimic human sepsis? Crit. Care Med. 32, S219-S222 (2004).
24. Parker, M. M. & Parillo, J. E. Septic shock. Hemodynamics and pathogenesis. JAMA 250, 3324-3327 (1983).
25. Abraham, E., Shoemaker, W. C., Bland, R. D. & Cobo, J. C. Sequential cardiorespiratory patterns in septic shock. Crit. Care Med. 11, 799-803 (1983).
26. Groeneveld, A. B., Bronsveld, W. & Thijs, L. G. Hemodynamic determinants of mortality in human septic shock. Surgery 99, 140-153 (1986).
27. Parker, M. M. et al. Profound but reversible myocardial depression in patients with septic shock. Ann. Intern. Med. 100, 483-490 (1984).
28. Parker, M. M., Shelhamer, J. H., Natanson, C., Alling, D. W. & Parillo, J. E. Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: Heart rate as an early predictor of prognosis. Crit. Care Med. 15, 923-929 (1987).
29. Ayala, A., Herdon, C. D., Lehman, D. L., Ayala, C. A. & Chaudry, I. H. Differential induction of apoptosis in lymphoid tissues during sepsis: variation in onset, frequency, and the nature of the mediators. Blood 87, 4261-4275 (1996).
30. Hotchkiss, R. S., Tinsley, K. W. & Karl, I. E. Role of apoptotic cell death in sepsis. Scand. J. Infect. Dis. 35, 585-592 (2003).
31. van der Poll, T. & van Deventer, S. J. Cytokines and anticytokines in the pathogenesis of sepsis. Infect. Dis. Clin. North. Am. 13, 413-426 (1999).
32. Sparwasser, T. et al. Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor-α-mediated shock. Eur. J. Immunol. 27, 1671-1679 (1997).
33. Hemmi, H. et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740-745 (2000).
34. Meng, G. et al. Antagonistic antibody prevents toll-like receptor 2-driven lethal shock-like syndromes. J. Clin. Invest. 113, 1473-1481 (2004).
35. Galanos, C., Freudenberg, M. A. & Reutter, W. Galactosamine-induced sensitization of the lethal effects of endotoxin. Proc. Natl. Acad. Sci. USA 76, 5939-5943 (1979).
36. Beutler, B. & Poltorak, A. Sepsis and evolution of the innate immune response. Crit. Care Med. 29, S2-S6 (2001).
37. Cohen, J. The immunopathogenesis of sepsis. Nature 420, 885-891 (2002).
38. Pfeffer, K. et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73, 457-467 (1993).
39. Rothe, J. et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 364, 798-802 (1993).
40. Bozza, M. et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J. Exp. Med. 189, 341-346 (1999).
41. Xu, H. et al. Leukocytosis and resistance to septic shock in intercellular adhesion molecule 1-deficient mice. J. Exp. Med. 180, 95-109 (1994).
42. Ayala, A., Deol, Z. K., Lehman, D. F., Herdon, C. D. & Chaudry, I. H. Polymicrobial sepsis but not low-dose endotoxin infusion causes decreased splenocyte IL-2/IFN-γ release while increasing IL-4/IL-10 production. J. Surg. Res. 56, 579-585 (1994).
43. Ayala, A., Song, G. Y., Chung, C. S., Redmond, K. M. & Chaudry, I. H. Immune depression in polymicrobial sepsis: The role of necrotic (injured) tissue and endotoxin. Crit. Care Med. 28, 2949-2955 (2000).
44. Remick, D. G., Newcomb, D. E., Bolgos, G. F. & Call, D. R. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 13, 110-116 (2000).
45. Zantl, N. et al. Essential role of γ-interferon in survival of colon ascendens stent peritonitis, a novel murine model of abdominal sepsis. Infect. Immun. 66, 2300-2309 (1998).
46. Copeland, S., Warren, H. S., Lowry, S. F., Calvano, S. E. & Remick, D. Acute inflammatory response to endotoxin in mice and humans. Clin. Diagn. Lab. Immunol. 12, 60-67 (2005).
47. Cross, A. S., Opal, S. M., Sadoff, J. C. & Gemski, P. Choice of bacteria in animal models of sepsis. Infect. Immun. 61, 2741-2747 (1993).
48. Rubins, J. B. & Pomeroy, C. Role of γ-interferon in the pathogenesis of bacteremic pneumococcal pneumonia. Infect. Immun. 65, 2975-2977 (1997).
49. Sawa, T. et al. IL-10 improves lung injury and survival in Pseudomonas aeruginosa pneumonia. J. Immunol. 159, 2858-2866 (1997).
50. Kohler, J. et al. IFN-γ involvement in the severity of gram-negative infections in mice. J. Immunol. 151, 916-921 (1993).
51. Sasaki, S. et al. Interleukin-4 and interleukin-10 are involved in host resistance to Staphylococcus aureus infection through regulation of γ-interferon. Infect. Immun. 68, 2424-2430 (2000).
52. Silva, A. T. & Cohen, J. Role of interferon-γ in experimental gram-negative sepsis. J. Infect. Dis. 166, 331-335 (1992).
53. Zanetti, G. et al. Cytokine production after intravenous or peritoneal gram-negative bacterial challenge in mice. Comparative protective efficacy of antibodies to tumor necrosis factor-α and to lipopolysaccharide. J. Immunol. 148, 1890-1897 (1992).
54. Evans, G. F., Snyder, Y. M., Butler, L. D. & Zuckerman, S. H. Differential expression of interleukin-1 and tumor necrosis factor in murine septic shock models. Circ. Shock 29, 279-290 (1989).
55. Greenberger, M. J. et al. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J. Immunol. 155, 722-729 (1995).
56. van der Poll, T., Marchant, A., Keogh, C. V., Goldman, M. & Lowry, S. F. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J. Infect. Dis. 174, 994-1000 (1996).
57. van der Poll, T. et al. Endogenous IL-10 protects mice from death during septic peritonitis. J. Immunol. 155, 5397-5401 (1995).
58. Moore, T. A., Perry, M. L., Getsoian, A. G., Newstead, M. W. & Standiford, T. J. Divergent role of γ-interferon in a murine model of pulmonary versus systemic Klebsiella pneumoniae infection. Infect. Immun. 70, 6310-6318 (2002).
59. Mizrachi-Nebenzahl, Y. et al. Differential activation of the immune system by virulent Streptococcus pneumoniae strains determines recovery or death of the host. Clin. Exp. Immunol. 134, 23-31 (2003).
60. Parker, S. J. & Watkins, P. E. Experimental models of gram-negative sepsis. Br. J. Surg. 88, 22-30 (2001).
61. Remick, D. G., Bolgos, G., Copeland, S. & Siddiqui, J. Role of interleukin-6 in mortality from and physiologic response to sepsis. Infect. Immun. 73, 2751-2757 (2005).
62. Remick, D. G., Bolgos, G. R., Siddiqui, J., Shin, J. & Nemzek, J. A. Six at six: Interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 17, 463-467 (2002).
63. Latifi, S. Q., O'Riordan, M. A. & Levine, A. D. Interleukin-10 controls the onset of irreversible septic shock. Infect. Immun. 70, 4441-4446 (2002).
64. Ayala, A. & Chaudry, I. H. Immune dysfunction in murine polymicrobial sepsis: Mediators, macrophages, lymphocytes and apoptosis. Shock 6 (Suppl. 1), S27-S38 (1996).
65. Maier, S. et al. Cecal ligation and puncture versus colon ascendens stent peritonitis: Two distinct animal models for polymicrobial sepsis. Shock 21, 505-511 (2004).
66. Oberholzer, A. et al. Increased survival in sepsis by in vivo adenovirus-induced expression of IL-10 in dendritic cells. J. Immunol. 168, 3412-3418 (2002).
67. Baker, C. C., Chaudry, I. H., Gaines, H. O. & Baue, A. E. Evaluation of factors affecting mortality rate after sepsis in a murine cecal ligation and puncture model. Surgery 94, 331-335 (1983).
68. Singleton, K. D. & Wischmeyer, P. E. Distance of cecum ligated influences mortality, tumor necrosis factor-α and interleukin-6 expression following cecal ligation and puncture in the rat. Eur. Surg. Res. 35, 486-491 (2003).
69. Turnbull, I. R. et al. Antibiotics improve survival in sepsis independent of injury severity but do not change mortality in mice with markedly elevated interleukin 6 levels. Shock 21, 121-125 (2004).
70. Heuer, J. G. et al. Evaluation of protein C and other biomarkers as predictors of mortality in a rat cecal ligation and puncture model of sepsis. Crit. Care Med. 32, 1570-1578 (2004).
71. Feterowski, C. et al. CC chemokine receptor 2 regulates leukocyte recruitment and IL-10 production during acute polymicrobial sepsis. Eur. J. Immunol. 34, 3664-3673 (2004).
72. Emmanuilidis, K. et al. Critical role of Kupffer cell-derived IL-10 for host defense in septic peritonitis. J. Immunol. 167, 3919-3927 (2001).
73. Weighardt, H. et al. Cutting edge: Myeloid differentiation factor 88 deficiency improves resistance against sepsis caused by polymicrobial infection. J. Immunol. 169, 2823-2827 (2002).
74. Feterowski, C. et al. Effects of functional Toll-like receptor-4 mutations on the immune response to human and experimental sepsis. Immunology 109, 426-431 (2003).
75. Entleutner, M. et al. Impact of interleukin- 12, oxidative burst, and iNOS on the survival of murine fecal peritonitis. Int. J. Colorectal Dis. 9 March 2005 [epub ahead of print].
76. Hensler, T. et al. Increased susceptibility to postoperative sepsis in patients with impaired monocyte IL-12 production. J. Immunol. 161, 2655-2659 (1998).
77. Weighardt, H. et al. Impaired monocyte IL-12 production before surgery as a predictive factor for the lethal outcome of postoperative sepsis. Ann. Surg. 235, 560-567 (2002).
78. Biondo, S. et al. Prognostic factors for mortality in left colonic peritonitis: A new scoring system. J. Am. Coll. Surg. 191, 635-642 (2000).
79. Echtenacher, B., Falk, W., Mannel, D. N. & Krammer, P. H. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J. Immunol. 145, 3762-3766 (1990).
80. Echtenacher, B., Mannel, D. N. & Hultner, F. Critical protective role of mast cells in a model of acute septic peritonitis. Nature 381, 75-77 (1996).
81. Echtenacher, B., Freudenberg, M. A., Jack, R. S. & Mannel, D. N. Differences in innate defense mechanisms in endotoxemia and polymicrobial septic peritonitis. Infect. Immun. 69, 7271-7276 (2001).
82. Echtenacher, B., Weigl, K., Lehn, N. & Mannel, D. N. Tumor necrosis factor dependent adhesions as a major protective mechanism early in septic peritonitis in mice. Infect. Immun. 69, 3550-3555 (2001).
83. Michie, H. R. et al. Detection of circulating tumor necrosis factor after endotoxin administration. N. Engl. J. Med. 318, 1481-1486 (1988).
84. Tracey, K. J. et al. Shock and tissue injury induced by recombinant human cachectin. Science 234, 470-474 (1986).
85. Tracey, K. J. et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330, 662-664 (1987).
86. Eskandari, M. K. et al. Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J. Immunol. 148, 2724-2730 (1992).
87. Alexander, H. R. et al. Treatment with recombinant human tumor necrosis factor-α protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis. J. Clin. Invest. 88, 34-39 (1991).
88. Fisher, C. J. Jr. et al. Treatment of septic shock with the tumor necrosis factor receptor:FC fusion protein. The Soluble TNF Receptor Sepsis Study Group. N. Engl. J. Med. 334, 1697-1702 (1996).
89. Eichacker, P. Q. et al. Risk and the efficacy of antiinflammatory agents: Retrospective and confirmatory studies of sepsis. Am. J. Respir. Crit. Care Med. 166, 1197-1205 (2002).
90. Shua, F. et al. Activated protein C suppresses tissue factor expression on U937 cells in the endothelial protein C receptor-dependent manner. FEBS Lett. 477, 208-212 (2000).
91. Sakata, Y., Loskutoff, D. J., Gladson, C. L., Hekman, C. M. & Griffin, J. H. Mechanism of protein C-dependent clot lysis: Role of plasminogen activator inhibitor. Blood 68, 1218-1223 (1986).
92. Schmidt-Supprian, M. et al. Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes. Eur. Cytokine Netw. 11, 407-413 (2000).
93. Murakami, K. et al. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am. J. Physiol. 272, L197-L202 (1997).
94. Grinnell, B. W., Hermann, R. B. & Yan, S. B. Human protein C inhibits selectin-mediated cell adhesion: Role of unique fucosylated oligosaccharide. Glycobiology 4, 221-225 (1994).
95. Dhainaut, J. F., Yan, S. B. & Claessens, Y. E. Protein C/activated protein C pathway: Overview of clinical trial results in severe sepsis. Crit. Care Med. 32, S194-S201 (2004).
96. Fourrier, F et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 101, 816-823 (1992).
97. Mesters, R. M. et al. Prognostic value of protein C concentrations in neutropenic patients at high risk of severe septic complications. Crit Care Med. 28, 2209-2216 (2000).
98. Yan, S. B. & Dhainaut, J. F. Activated protein C versus protein C in severe sepsis. Crit. Care Med. 29, S69-S74 (2001).
99. Iba, T et al. Association between the severity of sepsis and the changes in hemostatic molecular markers and vascular endothelial damage markers. Shock 23, 25-29 (2005).
100. Taylor, F. B., Jr. et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J. Clin. Invest. 79, 918-925 (1987).
101. Murakami, K. et al. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 87, 642-647 (1996).
102. Coalson, J. J. et al. A pathologic study of Escherichia coli shock in the baboon and the response to adrenocorticosteroid treatment. Surg. Gynecol. Obstet. 147, 726-736 (1978).
103. Hinshaw, L. B. et al. Survival of primates in lethal septic shock following delayed treatment with steroid. Circ. Shock 8, 291-300 (1981).
104. Levi, M. et al. Aggravation of endotoxin-induced disseminated intravascular coagulation and cytokine activation in heterozygous protein-C-deficient mice. Blood 101, 4823-4827 (2003).
105. Ganopolsky, J. G. & Castellino, F. J. A protein C deficiency exacerbates inflammatory and hypotensive responses in mice during polymicrobial sepsis in a cecal ligation and puncture model. Am. J. Pathol. 165, 1433-1446 (2004).
106. Laterre, P. F. et al. Hospital mortality and resource use in subgroups of the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial. Crit. Care Med. 32, 2207-2218 (2004).
107. Ward, P. A. et al. Anti-complement strategies in experimental sepsis. Scand. J. Infect. Dis. 35, 601-603 (2003).